Literature DB >> 28953016

Nodular Vasculitis in a Patient With Crohn's Disease on Vedolizumab.

Delila Pouldar1, Ashley Elsensohn2, Francesca Ortenzio2, Jessica Shiu2, Michael McLeod2, Sébastien de Feraudy2.   

Abstract

Erythema induratum (EI), or nodular vasculitis (NV), is a type of panniculitis that is often associated with vasculitis affecting various-sized veins, venules, and arteries in reaction to various causative factors. Historically, EI was highly linked to tuberculosis, but in 1946, Montgomery first proposed the term NV to describe cases of EI not associated with tuberculosis. Only 2 reports of NV associated with inflammatory bowel disease have been reported in the literature. The authors report a 60-year-old woman with Crohn's disease presenting with exacerbation of NV in the setting of vedolizumab therapy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28953016      PMCID: PMC6075649          DOI: 10.1097/DAD.0000000000001003

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  5 in total

Review 1.  The safety of vedolizumab for the treatment of ulcerative colitis.

Authors:  Gregor Novak; Pieter Hindryckx; Reena Khanna; Vipul Jairath; Brian G Feagan
Journal:  Expert Opin Drug Saf       Date:  2017-03-05       Impact factor: 4.250

2.  Erythema induratum (nodular vasculitis) associated with Crohn's disease: a rare type of metastatic Crohn's disease.

Authors:  Noriyuki Misago; Yutaka Narisawa
Journal:  Am J Dermatopathol       Date:  2012-05       Impact factor: 1.533

3.  Nodular vasculitis - a novel cutaneous manifestation of autoimmune colitis.

Authors:  Olga Pozdnyakova; Amit Garg; Meera Mahalingam
Journal:  J Cutan Pathol       Date:  2008-03       Impact factor: 1.587

4.  Nodular Vasculitis That Developed during Etanercept (Enbrel) Treatment in a Patient with Psoriasis.

Authors:  Seung-Bae Park; In-Kyu Chang; Myung Im; Young Lee; Chang-Deok Kim; Young-Joon Seo; Jeung-Hoon Lee
Journal:  Ann Dermatol       Date:  2015-10-02       Impact factor: 1.444

5.  Intractable pyoderma gangrenosum in a Crohn's disease patient on vedolizumab.

Authors:  Jennifer E Yeh; William G Tsiaras
Journal:  JAAD Case Rep       Date:  2017-03-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.